Wide World of Stocks Secures Agreements with WNBC and ION Television Networks

PORT JEFFERSON, N.Y.--(BUSINESS WIRE)--Wide World of Stocks, a new 30-minute pre-recorded television and website program that features microcap companies, has secured agreements with WNBC Channel 4 in New York and ION Television Network. As a result, the program is expected to reach more than 100 million households nationwide. The program’s producers aspire to scour the globe in search of microcap equities with the potential to become the next big market mover. The show will debut Wednesday, July 8, at noon, on NBC directly after Martha Stewart Living. The first episode will feature Viral Genetics’ (OTCPK: VRAL.PK) CEO, Mr. Haig Keledjian. Viral Genetics is developing drug therapies for HIV/AIDS, Lyme Disease, and other autoimmune diseases.

Additional WNBC broadcasts are scheduled for noon on Sunday, July 12^th and Sunday, July 19^th, just after The Wall Street Journal Report. The current broadcast schedule is still evolving as producers for Wide World of Stocks make additional media buys. As agreements are developed with more networks, the schedule will be updated and posted online at www.wideworldofstocks.com, where episodes of the program will be available for viewing after the fist WNBC broadcast.

Viral Genetics was chosen for the first episode of Wide World of Stocks. The company’s drug compound called VGV-1, has already undergone five clinical trials overseas, where it was found to reduce the viral load and symptoms of HIV/AIDS. Due to its novel mechanism, low toxicity profile, simple dosing regimen, and short course of treatment, researches at the company believe its therapy called “thymus nuclear protein,” (TNP) is extremely promising for other applications as well. Details about regarding the status of Viral Genetics’ drug compound and TNP therapy are available at www.viralgenetics.com.

Wide World of Stocks will be hosted by Damon Roberts with co-hosts Roland Rick Perry and Thomas McCarthy, "The Dean" of CollegeStock.com. Each of the hosts manages their own websites that combined reach more than 550,000 subscribers.

About Viral Genetics, Inc.:

Viral Genetics, Inc. is engaged in the discovery and development of immune-based therapies for HIV/AIDS and other autoimmune diseases using its thymus nuclear protein compound (TNP). Viral Genetics believes that its investigational HIV/AIDS drug based on TNP, called VGV-1, represents a unique approach to treating HIV/AIDS that focuses on boosting the immune system to allow the body to fight HIV more efficiently. See: www.viralgenetics.com. None of the information contained on this website is incorporated by reference herein.

Not a Broker/Dealer or Financial Advisor:

We are not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be a Registered Broker/Dealer or Financial Advisor. All materials presented in this press release, television show and on our website are not to be regarded as investment advice and are only for informative purposes. Readers should verify all claims and do their own due diligence before investing in featured companies. Investing in small-cap, micro cap and penny stock securities is speculative and carries a high degree of risk.

No Offer of Securities:

None of the information featured in this press release constitutes an offer or solicitation to purchase or to sell any securities of Viral Genetics, Inc.

Current Ownership of Shares:

Affiliates of Wild World Of Stocks, Inc. currently own securities of Viral Genetics, Inc. This is an inherent conflict of interest.

Compensation:

An Affiliate of Wide World Of Stocks, Inc. has agreed to provide consulting services to Viral Genetics, Inc. in exchange for up to 19 million shares of common stock and 12 million warrants of Viral Genetics, Inc. upon the completion of certain milestones. This is an inherent conflict of interest. As of the date of this press release, no shares of common stock or warrants have been issued pursuant to this agreement.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:

Information presented in this press release contains "forward looking statements" within the meaning of Section 27A of the Securities Exchange Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results.

None of the information contained on our website, www.wideworldofstocks.com, is incorporated by reference herein.